Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma

Written by Guru Sonpavde MD

Source: PracticeUpdate

Categories: Hem/Oncs, Latest Headlines

Tags: RadicalCystectomy, trial, urothelialcarcinoma

Tweets with this article

Guru Sonpavde, MD

Adjuvant Nivolumab extended DFS in overall & PD-L1+ High-Risk Muscle-Invasive #UrothelialCarcinoma following #RadicalCystectomy in Phase III CHECKMATE274 #trial -awaiting presentation of data @bmsnews @MattGalsky https://t.co/dlV5EIwO4H via @practiceupdate

2024 Top Story in Oncology: Emergence of Neoadjuvant Chemoimmunotherapy for Muscle-Invasive Bladder Cancer

Read it now on PracticeUpdate.com

Guru Sonpavde, MD December 13, 2024

Year in Review 2024 – Bladder Cancer

A video from Guru Sonpavde (as part of Oncology 2024 Year in Review), posted on Dec 2, 2024.

Guru Sonpavde, MD December 3, 2024

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment

A video from Guru Sonpavde (as part of 2024 ESMO Annual Meeting Insights Hub), posted on Sep 24, 2024.

Guru Sonpavde, MD October 6, 2024

CloudCME® – CE Platform

The CloudCME® learning management system (LMS) provides application, registration, evaluation, certificate, transcript, faculty, scheduling and disclosure collection & PARS, NARS & CPEMonitor reporting in one…

Guru Sonpavde, MD September 27, 2024